Annual Total Assets
$101.02 M
-$22.64 M-18.31%
31 December 2023
Summary:
Lineage Cell Therapeutics annual total assets is currently $101.02 million, with the most recent change of -$22.64 million (-18.31%) on 31 December 2023. During the last 3 years, it has fallen by -$6.93 million (-6.42%). LCTX annual total assets is now -42.12% below its all-time high of $174.54 million, reached on 31 December 2021.LCTX Total Assets Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Assets
$96.59 M
-$6.21 M-6.04%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly total assets is currently $96.59 million, with the most recent change of -$6.21 million (-6.04%) on 30 September 2024. Over the past year, it has dropped by -$9.56 million (-9.00%). LCTX quarterly total assets is now -56.46% below its all-time high of $221.87 million, reached on 30 September 2017.LCTX Quarterly Total Assets Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Total Assets Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -18.3% | -9.0% |
| 3 y3 years | -6.4% | -26.4% |
| 5 y5 years | -0.6% | -27.4% |
LCTX Total Assets High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -42.1% | at low | -44.7% | at low |
| 5 y | 5 years | -42.1% | at low | -44.7% | at low |
| alltime | all time | -42.1% | >+9999.0% | -56.5% | >+9999.0% |
Lineage Cell Therapeutics Total Assets History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $96.59 M(-6.0%) |
| June 2024 | - | $102.80 M(-5.2%) |
| Mar 2024 | - | $108.48 M(+7.4%) |
| Dec 2023 | $101.02 M(-18.3%) | $101.02 M(-4.8%) |
| Sept 2023 | - | $106.15 M(-5.0%) |
| June 2023 | - | $111.69 M(-1.3%) |
| Mar 2023 | - | $113.20 M(-8.5%) |
| Dec 2022 | $123.66 M(-29.2%) | $123.66 M(-5.7%) |
| Sept 2022 | - | $131.15 M(-3.5%) |
| June 2022 | - | $135.92 M(-5.9%) |
| Mar 2022 | - | $144.52 M(-17.2%) |
| Dec 2021 | $174.54 M(+61.7%) | $174.54 M(+33.0%) |
| Sept 2021 | - | $131.21 M(-2.6%) |
| June 2021 | - | $134.75 M(+5.3%) |
| Mar 2021 | - | $127.93 M(+18.5%) |
| Dec 2020 | $107.95 M(-14.0%) | $107.95 M(+4.7%) |
| Sept 2020 | - | $103.09 M(-8.0%) |
| June 2020 | - | $112.08 M(-5.7%) |
| Mar 2020 | - | $118.88 M(-5.3%) |
| Dec 2019 | $125.48 M(+23.4%) | $125.48 M(-5.6%) |
| Sept 2019 | - | $132.98 M(-12.3%) |
| June 2019 | - | $151.69 M(-17.4%) |
| Mar 2019 | - | $183.72 M(+80.7%) |
| Dec 2018 | $101.66 M(-41.3%) | $101.66 M(-42.3%) |
| Sept 2018 | - | $176.08 M(+56.9%) |
| June 2018 | - | $112.25 M(+1.7%) |
| Mar 2018 | - | $110.39 M(-36.3%) |
| Dec 2017 | $173.24 M(+21.5%) | $173.24 M(-21.9%) |
| Sept 2017 | - | $221.87 M(+14.7%) |
| June 2017 | - | $193.35 M(-5.8%) |
| Mar 2017 | - | $205.22 M(+43.9%) |
| Dec 2016 | $142.57 M(+50.6%) | $142.57 M(-3.4%) |
| Sept 2016 | - | $147.57 M(+41.5%) |
| June 2016 | - | $104.33 M(+30.2%) |
| Mar 2016 | - | $80.11 M(-15.4%) |
| Dec 2015 | $94.66 M(+26.4%) | $94.66 M(+23.2%) |
| Sept 2015 | - | $76.86 M(-3.5%) |
| June 2015 | - | $79.61 M(+14.2%) |
| Mar 2015 | - | $69.70 M(-6.9%) |
| Dec 2014 | $74.90 M(+29.7%) | $74.90 M(+34.6%) |
| Sept 2014 | - | $55.65 M(-15.7%) |
| June 2014 | - | $65.99 M(+13.9%) |
| Mar 2014 | - | $57.95 M(+0.4%) |
| Dec 2013 | $57.73 M(+94.1%) | $57.73 M(+87.1%) |
| Sept 2013 | - | $30.85 M(-22.7%) |
| June 2013 | - | $39.89 M(+13.0%) |
| Mar 2013 | - | $35.30 M(+18.7%) |
| Dec 2012 | $29.75 M(-35.1%) | $29.75 M(-9.5%) |
| Sept 2012 | - | $32.87 M(-14.4%) |
| June 2012 | - | $38.38 M(-1.5%) |
| Mar 2012 | - | $38.98 M(-15.0%) |
| Dec 2011 | $45.83 M(-14.0%) | $45.83 M(-9.9%) |
| Sept 2011 | - | $50.88 M(-4.8%) |
| June 2011 | - | $53.46 M(-6.0%) |
| Mar 2011 | - | $56.89 M(+6.8%) |
| Dec 2010 | $53.27 M(+296.6%) | $53.27 M(+29.0%) |
| Sept 2010 | - | $41.29 M(+20.9%) |
| June 2010 | - | $34.15 M(+168.9%) |
| Mar 2010 | - | $12.70 M(-5.5%) |
| Dec 2009 | $13.43 M(+1197.3%) | $13.43 M(+45.0%) |
| Sept 2009 | - | $9.27 M(+60.2%) |
| June 2009 | - | $5.78 M(+241.0%) |
| Mar 2009 | - | $1.70 M(+63.8%) |
| Dec 2008 | $1.04 M | $1.04 M(+0.9%) |
| Sept 2008 | - | $1.03 M(+68.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2008 | - | $609.50 K(+8.5%) |
| Mar 2008 | - | $561.70 K(+220.8%) |
| Dec 2007 | $175.10 K(-73.1%) | $175.10 K(+182.4%) |
| Sept 2007 | - | $62.00 K(-69.1%) |
| June 2007 | - | $200.60 K(-45.3%) |
| Mar 2007 | - | $366.60 K(-43.6%) |
| Dec 2006 | $650.50 K(-66.8%) | $650.50 K(-22.8%) |
| Sept 2006 | - | $842.60 K(-26.1%) |
| June 2006 | - | $1.14 M(-35.3%) |
| Mar 2006 | - | $1.76 M(-10.0%) |
| Dec 2005 | $1.96 M(+28.7%) | $1.96 M(+244.3%) |
| Sept 2005 | - | $569.00 K(-22.0%) |
| June 2005 | - | $729.30 K(-12.4%) |
| Mar 2005 | - | $832.80 K(-45.3%) |
| Dec 2004 | $1.52 M(+42.0%) | $1.52 M(-7.0%) |
| Sept 2004 | - | $1.64 M(-24.3%) |
| June 2004 | - | $2.16 M(-5.3%) |
| Mar 2004 | - | $2.28 M(+112.9%) |
| Dec 2003 | $1.07 M(-28.4%) | $1.07 M(-17.6%) |
| Sept 2003 | - | $1.30 M(+61.1%) |
| June 2003 | - | $806.90 K(-43.2%) |
| Mar 2003 | - | $1.42 M(-5.1%) |
| Dec 2002 | $1.50 M(-22.9%) | $1.50 M(-23.8%) |
| Sept 2002 | - | $1.96 M(+168.8%) |
| June 2002 | - | $730.20 K(-42.4%) |
| Mar 2002 | - | $1.27 M(-34.7%) |
| Dec 2001 | $1.94 M(+15.7%) | $1.94 M(-18.6%) |
| Sept 2001 | - | $2.38 M(+260.9%) |
| June 2001 | - | $660.40 K(-25.8%) |
| Mar 2001 | - | $890.40 K(-46.9%) |
| Dec 2000 | $1.68 M(-70.5%) | $1.68 M(-27.5%) |
| Sept 2000 | - | $2.31 M(-17.6%) |
| June 2000 | - | $2.81 M(-30.7%) |
| Mar 2000 | - | $4.05 M(-28.7%) |
| Dec 1999 | $5.68 M(+102.1%) | $5.68 M(-18.9%) |
| Sept 1999 | - | $7.00 M(-16.7%) |
| June 1999 | - | $8.40 M(-9.7%) |
| Mar 1999 | - | $9.30 M(+144.7%) |
| Dec 1998 | $2.81 M(-38.9%) | - |
| Sept 1998 | - | $3.80 M(-17.4%) |
| June 1998 | - | $4.60 M(-17.9%) |
| June 1998 | $4.60 M(-44.6%) | - |
| Mar 1998 | - | $5.60 M(-16.4%) |
| Dec 1997 | - | $6.70 M(-13.0%) |
| Sept 1997 | - | $7.70 M(-7.2%) |
| June 1997 | $8.30 M(+176.7%) | $8.30 M(+7.8%) |
| Mar 1997 | - | $7.70 M(+234.8%) |
| Dec 1996 | - | $2.30 M(-8.0%) |
| Sept 1996 | - | $2.50 M(-16.7%) |
| June 1996 | $3.00 M(-16.7%) | $3.00 M(0.0%) |
| Sept 1995 | - | $3.00 M(-16.7%) |
| June 1995 | $3.60 M(-39.0%) | $3.60 M(-12.2%) |
| Mar 1995 | - | $4.10 M(-12.8%) |
| Dec 1994 | - | $4.70 M(-14.5%) |
| Sept 1994 | - | $5.50 M(-6.8%) |
| June 1994 | $5.90 M(+68.6%) | $5.90 M(-7.8%) |
| Mar 1994 | - | $6.40 M(+128.6%) |
| Dec 1993 | - | $2.80 M(-20.0%) |
| Sept 1993 | - | $3.50 M(0.0%) |
| June 1993 | $3.50 M(-27.1%) | $3.50 M(-10.3%) |
| Mar 1993 | - | $3.90 M(-4.9%) |
| Dec 1992 | - | $4.10 M(-8.9%) |
| Sept 1992 | - | $4.50 M(-6.3%) |
| June 1992 | $4.80 M | $4.80 M(-7.7%) |
| Mar 1992 | - | $5.20 M |
FAQ
- What is Lineage Cell Therapeutics annual total assets?
- What is the all time high annual total assets for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual total assets year-on-year change?
- What is Lineage Cell Therapeutics quarterly total assets?
- What is the all time high quarterly total assets for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly total assets year-on-year change?
What is Lineage Cell Therapeutics annual total assets?
The current annual total assets of LCTX is $101.02 M
What is the all time high annual total assets for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual total assets is $174.54 M
What is Lineage Cell Therapeutics annual total assets year-on-year change?
Over the past year, LCTX annual total assets has changed by -$22.64 M (-18.31%)
What is Lineage Cell Therapeutics quarterly total assets?
The current quarterly total assets of LCTX is $96.59 M
What is the all time high quarterly total assets for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly total assets is $221.87 M
What is Lineage Cell Therapeutics quarterly total assets year-on-year change?
Over the past year, LCTX quarterly total assets has changed by -$9.56 M (-9.00%)